A Network Meta-Analysis of the Systemic Therapies in Unresectable Head and Neck Squamous Cell Carcinoma
| Title: | A Network Meta-Analysis of the Systemic Therapies in Unresectable Head and Neck Squamous Cell Carcinoma |
|---|---|
| Authors: | Jinling Yuan MMed, Kexin Shi MMed, Guanhua Chen MMed, Weilin Xu MMed, Lei Qiu MMed, Yinjiao Fei MMed, Yuchen Zhu MMed, Mengxing Wu MMed, Yurong Li MMed, Xinchen Sun MD, Yuandong Cao MD, Shu Zhou MMD |
| Source: | Cancer Control, Vol 31 (2024) |
| Publisher Information: | SAGE Publishing, 2024. |
| Publication Year: | 2024 |
| Collection: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: | Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: | The current standard treatment for locally advanced squamous cell carcinoma of the head and neck (LASCCHN) comprises concurrent radiotherapy (CRT) alongside platinum-based chemotherapy. However, innovative therapeutic alternatives are being evaluated in phase II/III randomized trials. This study employed a Bayesian network meta-analysis (NMA) using fixed effects to provide both direct and indirect comparisons of all existing treatment modalities for unresectable LASCCHN. Methods: We referenced randomized controlled trials (RCTs) from January 2000 to July 2023 by extensively reviewing PubMed, EMBASE, and Web of Science databases, adhering to the Cochrane methodology. Relevant data, including summary estimates of overall survival (OS) and progression-free survival (PFS), were extracted from these selected studies and recorded in a predefined database sheet. Subsequently, we conducted a random effects network meta-analysis using a Bayesian framework. Results: Based on the Surface Under the Cumulative Ranking (SUCRA) values, the league table organizes the various treatments for OS in the following order: IC + RT&MTT, MTT-CRT, IC + CRT&MTT, CRT, IC + CRT, MTT-RT, IC + MTT-RT, and RT. In a similar order, the treatments rank as follows according to the league table: IC + CRT&MTT, MTT-CRT, IC + CRT, IC + RT&MTT, CRT, IC + MTT-RT, MTT-RT, and RT. Notably, none of these treatments showed significant advantages over concurrent chemoradiotherapy. Conclusion: Despite concurrent chemoradiotherapy being the prevailing treatment for LASCCHN, our findings suggest the potential for improved outcomes when concurrent chemoradiotherapy is combined with targeted therapy or induction chemotherapy. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 1526-2359 10732748 |
| Relation: | https://doaj.org/toc/1526-2359 |
| DOI: | 10.1177/10732748241255535 |
| Access URL: | https://doaj.org/article/c9a60a056f6146298d9b1aff76da79f9 |
| Accession Number: | edsdoj.9a60a056f6146298d9b1aff76da79f9 |
| Database: | Directory of Open Access Journals |
| ISSN: | 15262359 10732748 |
|---|---|
| DOI: | 10.1177/10732748241255535 |
| Published in: | Cancer Control |
| Language: | English |